

Comparison of LMA Protector vs. endotracheal tube in patients undergoing laparoscopic surgery: a randomised controlled trial

Mehmet Yilmaz¹, Ayse Z. Turan¹, Ayten Saracoglu², Kemal T. Saracoglu³

¹Department of Anesthesiology and Intensive Care, Derince Research and Education Hospital, Health Sciences University, Kocaeli, Turkey

²Department of Anesthesiology and Intensive Care, Marmara University Medical School, Istanbul, Turkey

³Department of Anesthesiology and Intensive Care, Kartal Dr. Lütfi Kırdar Research and Education Hospital, Health Sciences University, Istanbul, Turkey

Abstract

Background: Recent advances in airway management have led to supraglottic airway devices (SAD) being increasingly often chosen instead of tracheal intubation for laparoscopic surgery. However, there are ongoing arguments regarding the use of SAD due to worries about the risks of insufficient ventilation and pulmonary aspiration. The LMA Protector is a second generation SAD which was put into use recently. This prospective randomised trial investigated whether the LMA Protector was comparable to the tracheal tube regarding respiratory parameters, perioperative complications and haemodynamic parameters in patients undergoing laparoscopic surgery.

Methods: A total of 154 adult patients were randomised to two groups: Group 1 (tracheal intubation) and Group 2 (LMA Protector). Achieving adequate depth of anaesthesia, the patients were either intubated or the LMA Protector was placed. The initial baseline measurements were recorded including tidal volume, peak inspiratory pressure (PIP), oropharyngeal leak pressure (OLP) and haemodynamic parameters. These measurements were repeated and recorded again following pneumoperitoneum and recovery from anaesthesia.

Results: At the mean age of 52.22 ± 13.90 years 77 patients were intubated and in 77 patients the LMA Protector was applied. Following insertion of the airway device and pneumoperitoneum, the heart rate was higher in the intubation group. In the LMA Protector group OLP measures were found to be statistically similar. The mean Brimacombe fiberoptic visualisation score was 2.12 ± 0.58 and the rate of requirement of optimisation was 15% in the LMA Protector group.

Conclusions: With high OLP, better haemodynamic parameters and low laryngeal view scores, we concluded that the LMA Protector can be used safely in patients undergoing laparoscopic surgery.

Key words: laparoscopic surgery, anaesthesia, intubation, LMA protector.

Anaesthesiol Intensive Ther 2022;54, 3:247–252

Received: 31.08.2021, accepted: 08.09.2022

CORRESPONDING AUTHOR:

Dr. Mehmet Yilmaz, Department of Anesthesiology, and Intensive Care, Derince Research and Education Hospital, Health Sciences University, Kocaeli, Turkey, e-mail: drmyilmaz33@gmail.com

Recent advances in airway management led to an increasing frequency of supraglottic airway devices (SAD) being chosen instead of tracheal intubation for laparoscopic procedures. However, there are ongoing arguments regarding the use of SAD due to worries about the risks of insufficient ventilation and pulmonary aspiration [1].

The effectiveness of second-generation SAD such as Auragain, i-gel, Proseal or Supreme has been sought in laparoscopic surgery patients [2–4]. However, there has not been a single SAD advised by demonstrating clear safety in these types of procedures.

The LMA Protector (TeleflexMedical Europe Ltd., Athlone, Ireland) is a second-generation SAD that was put into use recently [5]. Due to its structure and properties, the risk of gastric aspiration is minimised [6]. It has a stable curved form and is intended for single use [7]. The first clinical trials with this device reported a high rate of success of placement in the first attempt and an adequate and reliable airway seal at the same time [8, 9].

This prospective randomised trial investigated whether the LMA Protector was comparable to tracheal tube regarding respiratory parameters. Our primary outcome was to evaluate the oropha-

ryngeal leak pressure (OLP) values for the LMA Protector and compare the peak airway pressure between groups. The secondary outcome was to determine the Brimacombe fiberoptic visualisation scores and compare haemodynamic parameters in patients undergoing laparoscopic surgery.

METHODS

After Institutional Review Board approval from our university (IRB #2017/406) and registration at <https://clinicaltrials.gov> (NCT03453138), 157 adult patients with informed written consent obtained between 01.03.2018 and 01.05.2018 were enrolled in our study. Three of these were excluded due to conversion to open surgery. Patients who refused to be included in the study, patients with a history or sign of difficult intubation in their preoperative evaluation, and patients with respiratory system disorders such as chronic obstructive pulmonary disease, emphysema, or pulmonary oedema were excluded from the study. The patients were randomised to two groups: Group 1 (tracheal intubation) and Group 2 (LMA Protector). Randomisation was performed using the True Random Number Generator from www.random.org.

Neither of the groups of patients was treated with any preoperative premedications. Standard monitoring included pulse oximetry, electrocardiography, and non-invasive blood pressure. Anaesthesia was induced with intravenous propofol (2–3 mg kg⁻¹), fentanyl (1–2 µg kg⁻¹) and rocuronium bromide (0.6 mg kg⁻¹). Achieving adequate depth of anaesthesia, the patients were either intubated, or the LMA Protector was placed. Tracheal intubation time was started as soon as the operator handled the laryngoscope until a proper end-tidal CO₂ trace was observed. Tracheal tubes of 8.0–8.5 mm ID were used for male patients, whereas 7.0–7.5 mm ID tubes were used for female patients. In the LMA Protector group, the timer was started as soon as the operator handled the LMA Protector and not stopped until a proper end-tidal CO₂ trace was observed. The number of attempts and success rates were recorded. The cuff pressures were maintained in the appropriate pressure range using a cuff manometer. Brimacombe image classification, which was based on visualisation of the vocal cords by a fiberoptic bronchoscope through the SAD, was made; Class 1: Vocal cords cannot be seen, Class 2: Vocal cords and anterior epiglottis can be seen, Class 3: Vocal cords and posterior epiglottis can be seen, and Class 4: Only vocal cords can be seen [10].

An intact patient airway was proven by visualisation of an appropriate end-tidal CO₂ trace and a tidal volume of 6–8 mL kg⁻¹. The following was

the mechanical ventilation mode that was standardised in the volume-controlled ventilation (VCV) mode: respiratory rate 12 min⁻¹, tidal volume 6 mL kg⁻¹, initial PEEP 5 cmH₂O. If necessary, PEEP and respiration rate were modified based on end-tidal CO₂. Then, the initial baseline measurements were recorded, including tidal volume, peak inspiratory pressure (PIP), OLP, mean arterial blood pressure (MAP), heart rate (HR), and peripheral oxygen saturation (SpO₂). These measurements were repeated and recorded again following pneumoperitoneum and recovery from anaesthesia.

Following surgery, patients were transported to the recovery room. Patients were monitored using the Modified Aldrete Scoring System (MASS), and when they reached a score of 9 points, they were transported to the service. Postoperative recovery duration and presence of complications such as sore throat, dysphonia, and dysphagia were recorded in the recovery room. The complications were evaluated blindly by researchers who were unaware of the groups. Additionally, the number of attempts for placement of a nasogastric cannula through the gastric aspiration channel was recorded in the LMA Protector group.

Statistical analysis

IBM SPSS Statistics 22 program was used to evaluate the findings of this study. Among the numeric data, the independent samples *t*-test was used for those with a normal distribution, the Mann-Whitney *U* test was used for those that do not follow a normal distribution, the χ^2 test was used for discrete variables, and the Kruskal-Wallis *H* test was used for evaluation of time periods of cuff leakage. The results were evaluated with the 95% confidence interval and the significance level $P < 0.05$. The sample size was calculated based on a preliminary study of 10 patients in each group. Cuff leak at pre-extubation and cuff leak at 5 minutes were measured in patients in the LMA Protector group and were 30.50 ± 5.89 and 33.60 ± 4.79 mmHg, respectively. We determined that 50 patients in each group would be sufficient with an 80% sample size ($\alpha = 0.05$, $\beta = 0.2$, and confidence interval = 95%), and the study was completed with 77 patients in each group.

RESULTS

Three patients were excluded, and the data analysis of 154 patients in total was performed (Figure 1). While 77 patients with an average age of 52.22 ± 13.90 years were intubated, the LMA Protector was used for the other 77 patients. In terms of age, body weight, height, thyromen-

tal distance, the Mallampati and American Society of Anesthesiologists (ASA) scores, the two groups were found to be similar, whereas there was a significant difference in gender distribution (Table 1).

The duration of anaesthesia, duration of surgery, the number of attempts at inserting the airway device, and duration of the recovery period were similar between the groups. Likewise, the tidal volumes and PIPs of the groups were similar. However, the duration of airway device insertion and the incidence of sore throat were found to be significantly different between the groups (Table 2). Hoarseness was not observed in any of our patients.

The preoperative HR, MAP, and SpO₂ values of the groups were found to be statistically similar. Although the MAP and end-tidal CO₂ values were similar following the insertion of the airway device, HR and SpO₂ values were significantly higher in the tracheal intubation group. Following pneumoperitoneum, MAP, SpO₂, and end-tidal CO₂ values were similar. However, HR was higher in the intubation group. Before extubation, HR, MAP, and SpO₂ values were similar. Following extubation, although HR and SpO₂ values were similar, MAP was statistically significantly higher in the intubation group (Table 3).

Also, in the LMA Protector group, OLP measures were found to be statistically similar (Table 4).

The mean Brimacombe fiberoptic visualisation score was 2.12 ± 0.58 (mean \pm standard deviation), and the rate of the requirement of optimisation was 15% ($n = 12$) in the LMA Protector group.

DISCUSSION

Among the adult patients undergoing laparoscopic cholecystectomy, insertion of the LMA




FIGURE 1. Flow diagram of the study

Protector resulted in similar findings for ventilatory parameters; moreover, better results were obtained than tracheal intubation regarding haemodynamic parameters.

Abdominal insufflation during laparoscopic surgery reduces respiratory system compliance. Consequently, the upshift of the diaphragm causes an increase in airway pressure [11]. On the other hand, the resistance of the respiratory system rises due to increased airway pressure. Therefore, the two most important parameters to search for the safety of supraglottic airway devices are OLP and PIP. High PIP carries the risk of barotrauma for the lungs, also causing airway leakage and gastric insufflation if it exceeds OLP [12, 13]. In our study, these values were recorded as soon as the LMA Protector was placed, following pneumoperitoneum, and prior to recovery. PIP values were not found to be significantly different when compared to tracheal intubation.

TABLE 1. Demographic data of the groups

Factor	Group 1: Tracheal intubation, <i>n</i> = 77	Group 2: LMA Protector, <i>n</i> = 77	<i>P</i> -value
Gender			
Female	43	58	0.011 ^k
Male	34	19	
Age (years)	51.52 \pm 15.04	52.92 \pm 12.72	0.533 ^s
Weight (kg)	81 \pm 22.5 (81)	80 \pm 20 (80)	0.378 ^m
Height (cm)	165.65 \pm 8.45 (165)	164.04 \pm 7.79 (165)	0.276 ^m
ASA	1.97 \pm 0.57 (2)	1.88 \pm 0.46 (2)	0.802 ^m
Thyromental distance (cm)	7.54 \pm 1.30 (7)	7.93 \pm 1.53 (7.5)	0.067 ^m
Mallampati	1.74 \pm 0.71 (2)	1.74 \pm 0.73 (2)	0.986 ^m

^k χ^2 test: values are given as frequency (percentage)

^sIndependent samples *t*-test: values are given as mean \pm standard deviation

^mMann-Whitney *U* test: values are given as mean \pm standard deviation (median)

TABLE 2. Perioperative data of the groups

Factor	Group 1: Tracheal intubation, n = 77	Group 2: LMA Protector, n = 77	P-value
Duration of anaesthesia (min)	55.95 ± 15.52 (50)	55.61 ± 16.27 (50)	0.936 ^m
Duration of surgery (min)	49.17 ± 13.60 (45)	47.57 ± 14.79 (45)	0.261 ^m
Duration of insertion of the airway device (s)	11.49 ± 4.84 (10)	14.52 ± 7 (13)	0.004 ^m
Number of attempts on insertion	1.13 ± 0.82 (1)	1.1 ± 0.31 (1)	0.243 ^m
Tidal volume (mL)			
Initial	526.01 ± 44.62	541.86 ± 61.46	0.069 ^s
After pneumoperitoneum	538.12 ± 53.92	555.10 ± 70.31	0.095 ^s
Before extubation	531.30 ± 74.22 (535)	553.90 ± 54.35 (550)	0.068 ^m
PIP (cmH ₂ O)			
Initial	18.35 ± 3.85 (18)	17.74 ± 4.57 (17)	0.115 ^m
After pneumoperitoneum	19.06 ± 3.86 (19)	18.88 ± 4.95 (18)	0.458 ^m
Before extubation	19.99 ± 4.20 (20)	19.14 ± 3.86 (19)	0.196 ^m
Sore throat			
Yes	12	2	0.012 ^k
No	65	75	
Duration of recovery period (min)	11.03 ± 3.53 (10)	10.68 ± 4.86 (10)	0.076 ^m

^mMann-Whitney U test: values are given as mean ± standard deviation (median)

^sIndependent samples t-test: values are given as mean ± standard deviation

^kχ² test: values are given as frequency (percentage)

PIP – peak inspiratory pressure

The mean PIP value not exceeding 20 mmHg, as well as comparable values with tracheal intubation, suggest that this device can be safely used during laparoscopic procedures. Moreover, mean OLP values over 30 mmHg with the LMA Protector were a supporting finding for its safety.

In a meta-analysis including 26 studies with data from a total of 2142 patients, eight SAD were evaluated; the highest OLP values were obtained prior to the pneumoperitoneum period with Ambu Aura Gain, and the highest OLP values were obtained after the pneumoperitoneum period with the i-gel group [14]. The absence of a significant difference between the values obtained before and after the pneumoperitoneum periods in our study also gives information regarding the reliable use of the LMA Protector in laparoscopic procedures.

The LMA Protector has dual gastric access and integrates “Second Seal Technology/second generation LMA” to secure the distal tip at the upper oesophageal sphincter [15]. In this way an oesophageal seal is facilitated, and the respiratory tract is isolated from the digestive tract [7]. Therefore, it becomes possible to reduce the risk of gastric content aspiration. Our findings obtained in this study regarding the OLP and PIP values were in line with current literature. The LMA Protector was recently evaluated in 300 patients undergoing laparoscopic procedures, and the mean OLP was 30.18 ± 5.88 cmH₂O [16]. In another study,

the OLP for the LMA Protector was more than 5 cmH₂O higher than for the i-gel, where higher PIPs were also generated [17].

Because of the pressure due to tracheal cuff insufflation, sore throat and hoarseness may occur in the postoperative period of laparoscopic procedures [18, 19]. In our study, two patients in the LMA Protector group developed a sore throat, whereas this number increased to 12 in the tracheal intubation group. This finding indicated that, when compared with a tracheal tube, the LMA Protector applied less trauma to the vocal cords and trachea and caused less pressure injury on the pharynx. Vocal cord and trachea irritation is expected to be less with supraglottic airway devices due to their placement superior to the larynx. In a review that included 29 randomised prospective studies, the incidence rates of laryngospasm and cough were reported to be increased in the group of tracheal intubated patients undergoing laparoscopic surgery [20]. Moreover, in a meta-analysis including 1433 patients from 17 studies, the rate of successful insertion on the first attempt and the duration of device insertion were not found to be different between tracheal intubation and SAD groups [21].

Due to the increased risk of aspiration of the gastric contents during the pneumoperitoneum period, emptying the stomach with a nasogastric tube is important for patients who undergo lapa-

TABLE 3. Comparison of vital parameters between groups

Factor	Group 1: Tracheal intubation, <i>n</i> = 77	Group 2: LMA Protector, <i>n</i> = 77	<i>P</i> -value
Preoperative vital parameters			
MAP (mmHg)	104.88 ± 13.56 (103.67)	105.66 ± 15.05(104)	0.816 ^m
HR (beat/min)	83.53 ± 15.93 (83)	80.34 ± 15.35(77)	0.106 ^m
SpO ₂ (%)	95.73 ± 10.47 (98)	105.83 ± 68.62(98)	0.051 ^m
Vital parameters after airway device insertion			
MAP (mmHg)	91.65 ± 16.54	93.75 ± 17.99	0.451 ^s
HR (beat/min)	89.56 ± 16.55	81.08 ± 16.99	0.002 ^s
ETCO ₂ (mmHg)	33.84 ± 4.48 (34)	32.84 ± 3.93(32)	0.124 ^m
SpO ₂ (%)	99.56 ± 0.62 (100)	98.82 ± 1.64(100)	0.049 ^m
Vital parameters after pneumoperitoneum			
MAP (mmHg)	89.03 ± 14.60 (89)	93.60 ± 22.46(91)	0.329 ^m
HR (beat/min)	87.6 ± 15.19	81.17 ± 17.87	0.017 ^s
SpO ₂ (%)	98.91 ± 1.52 (99)	98.40 ± 1.77(99)	0.128 ^m
etCO ₂ (mmHg)	33.38 ± 3.13 (34)	32.53 ± 3.81(32)	0.095 ^m
Vital parameters before extubation			
MAP(mmHg)	94.83 ± 12.59 (96)	94.81 ± 17.51(93.33)	0.464 ^m
HR(beat/min)	76.46 ± 16.16 (75)	74.19 ± 15.21(74)	0.442 ^m
SpO ₂ (%)	99.21 ± 1.39 (100)	99.62 ± 0.61(100)	0.100 ^m
etCO ₂ (mmHg)	35.94 ± 3.64 (36)	34.82 ± 3.65(35)	0.220 ^m
Vital parameters after extubation			
MAP (mmHg)	112.68 ± 16.42	106.90 ± 13.53	0.018 ^s
HR (beat/min)	91.03 ± 16.17	90.16 ± 17.43	0.745 ^s
SpO ₂ (%)	98.84 ± 1.41 (99)	98.47 ± 1.72(99)	0.340 ^m

^mMann-Whitney *U*-test: values are given as mean ± standard deviation (median)

^sIndependent samples *t*-test: values are given as mean ± standard deviation

MAB – mean arterial blood pressure, HR – heart rate, etCO₂ – end-tidal CO₂, SpO₂ – peripheral oxygen saturation

TABLE 4. Oropharyngeal leak pressure (OLP) for LMA Protector group

	Minute 0	After pneumoperitoneum	At end of operation	<i>P</i> -value
OLP (mmHg)	32.88 ± 6.11 (30)	32.73 ± 7.71 (30)	33.65 ± 8.11 (32)	0.682 ^k

^kKruskal-Wallis *H*-test: values are given as mean ± standard deviation (median)

roscopic surgical interventions [22]. In this study, insertion of a nasogastric tube was mostly possible on the first attempt through the side channel of the LMA Protector.

Haemodynamic changes cause additional risks for the patient during intubation and extubation. Although the basal haemodynamic parameters were similar between the groups in our study, among the haemodynamic values, HR and MAP values were found to be higher in the tracheal intubation group than the LMA Protector group. Both laryngoscopy and tracheal intubation provide noxious stimuli leading to an adrenergic response [23]. Moreover, the receptors located in the upper airway are stimulated during the extubation as in laryngoscopy [24]. This was cited as one of the advantages of the LMA Protector tube.

According to the comparison of ventilation parameters, tidal volume, peak airway pressure, and the number of attempts for insertion were similar. This result may prove that the LMA Protector is as safe and useful as the tracheal tube to obtain an intact airway during laparoscopic surgery.

LIMITATIONS

The main limitation of this study is that, due to the structural properties of the LMA Protector, some parameters could not be compared with tracheal intubation. Therefore, fiberoptic visualisation score, ease of nasogastric insertion, and OLP were recorded as parameters related to the LMA Protector.

Another limitation of our study is the uneven gender distribution, which we believe is due to the fact that gallbladder diseases are more common in

women [25]. While the postoperative evaluations were blinded, the practitioners and observers who recorded the intraoperative data were not blind due to the nature of this study.

CONCLUSIONS

With high oropharyngeal cuff pressure, better haemodynamic parameters, and low laryngeal view scores, we concluded that the LMA Protector could be used safely in patients undergoing laparoscopic procedures.

ACKNOWLEDGMENTS

1. Financial support and sponsorship: none.
2. Conflicts of interest: none.
3. Presentation: The abstract of this study was presented as an oral presentation at the 5th European Airway Management Congress in Catania, Italy, on 6th December 2018. <https://doi.org/10.1016/j.tacc.2018.09.012>.

REFERENCES

1. Lai CJ, Liu CM, Wu CY, Tsai FF, Tseng PH, Fan SZ. I-gel is a suitable alternative to endotracheal tubes in the laparoscopic pneumoperitoneum and Trendelenburg position. *BMC Anesthesiol* 2017; 17: 3. doi: 10.1186/s12871-016-0291-1.
2. Parikh SS, Parekh SB, Doshi C, Vyas V. ProSeal laryngeal mask airway versus cuffed endotracheal tube for laparoscopic surgical procedures under general anesthesia: a random comparative study. *Anesth Essays Res* 2017; 11: 958-963. doi: 10.4103/aer.AER_97_17.
3. Lopez AM, Agusti M, Gambus P, Pons M, Anglada T, Valero R. A randomized comparison of the Ambu AuraGain versus the LMA supreme in patients undergoing gynaecologic laparoscopic surgery. *J Clin Monit Comput* 2017; 31: 1255-1262. doi: 10.1007/s10877-016-9963-0.
4. Singh K, Gurha P. Comparative evaluation of Ambu AuraGain™ with ProSeal™ laryngeal mask airway in patients undergoing laparoscopic cholecystectomy. *Indian J Anaesth* 2017; 61: 469-474. doi: 10.4103/ija.IJA_163_17.
5. Sorbello M, Cortese G, Gaçonnet C, Skinner M. A modified Bailey's manoeuvre for supraglottic airway continuum using LMA Protector™. *Indian J Anaesth* 2019; 63: 78-80. doi: 10.4103/ija.IJA_502_18.
6. Mendonca C, Tourville CC, Jefferson H, Nowicka A, Patteril M, Athanassoglou V. Fiberoptic-guided tracheal intubation through i-gel® and LMA® Protector™ supraglottic airway devices – a randomised comparison. *Anaesthesia* 2019; 74: 203-210. doi: 10.1111/anae.14475.
7. Eckardt F, Engel J, Mann ST, et al. LMA Protector™ Airway: first experience with a new second generation laryngeal mask. *Minerva Anestesiol* 2019; 85: 45-52. doi: 10.23736/S0375-9393.18.12421-7.
8. Sng BL, Ithnin FB, Mathur D, Lew E, Han NR, Sia AT. A preliminary assessment of the LMA Protector™ in non-paralysed patients. *BMC Anesthesiol* 2017; 17: 26. doi: 10.1186/s12871-017-0323-5.
9. Tan LZ, Tan DJ, Seet E. Laryngeal mask airway protector™: Advanced uses for laparoscopic cholecystectomies. *Indian J Anaesth* 2017; 61: 673-675. doi: 10.4103/ija.IJA_240_17.
10. Brimacombe J, Berry A. A proposed fiber-optic scoring system to standardize the assessment of laryngeal mask airway position. *Anesth Analg* 1993; 76: 457.
11. Hong SJ, Ko KM, Park JH, et al. Effectiveness of the Stream lined Liner of the Pharynx Airway (SLIPATM) in allowing positive pressure ventilation during gynaecological laparoscopic surgery. *Anaesth Intensive Care* 2011; 39: 618-622. doi: 10.1177/0310057X1103900413.
12. Tuxen DV, Lane S. The effects of ventilatory pattern on hyperinflation, airway pressures, and circulation in mechanical ventilation of patients with severe air-flow obstruction. *Am Rev Respir Dis* 1987; 136: 872-879. doi: 10.1164/ajrccm/136.4.872.
13. Wahlen BM, Heinrichs W, Latorre F. Gastric insufflation pressure, air leakage and respiratory mechanics in the use of the laryngeal mask airway (LMA) in children. *Paediatr Anaesth* 2004; 14: 313-317. doi: 10.1046/j.1460-9592.2003.01213.x.
14. Yoon SW, Kang H, Choi GJ, et al. Comparison of supraglottic airway devices in laparoscopic surgeries: a network meta-analysis. *J Clin Anesth* 2019; 55: 52-66. doi: 10.1016/j.jclinane.2018.12.044.
15. Cook TM, Gatward JJ, Handel J, et al. Evaluation of the LMA Supreme in 100 non-paralysed patients. *Anaesthesia* 2009; 64: 555-562. doi: 10.1111/j.1365-2044.2008.05824.x.
16. Liu Y, Song Y, Wang M, et al. LMA Protector™ in patients undergoing laparoscopic surgeries: a multicenter prospective observational study. *BMC Anesthesiol* 2021; 21: 318. doi: 10.1186/s12871-021-01535-y.
17. Acx E, Van Caelenberg E, De Baerdemaeker L, Coppens M. Laryngeal mask airway protector generates higher oropharyngeal leak pressures compared to the laryngeal mask airway supreme: a randomized clinical trial in the ambulatory surgery unit. *J Anaesthesiol Clin Pharmacol* 2021; 37: 221-225. doi: 10.4103/joacp.JOACP_416_19.
18. Kikura M, Suzuki K, Itagaki T, Takada T, Sato S. Age and comorbidity as risk factors for vocal cord paralysis associated with tracheal intubation. *Br J Anaesth* 2007; 98: 524-530. doi: 10.1093/bja/aem005.
19. Puthenveetil N, Kishore K, Paul J, Kumar L. Effect of cuff pressures on postoperative sore throat in gynecologic laparoscopic surgery: an observational study. *Anesth Essays Res* 2018; 12: 484-488. doi: 10.4103/aer.AER_72_18.
20. Yu SH, Beirne OR. Laryngeal mask airways have a lower risk of airway complications compared with endotracheal intubation: a systematic review. *J Oral Maxillofac Surg* 2010; 68: 2359-2376. doi: 10.1016/j.joms.2010.04.017.
21. Park SK, Ko G, Choi GJ, Ahn EJ, Kang H. Comparison between supraglottic airway devices and endotracheal tubes in patients undergoing laparoscopic surgery: a systematic review and meta-analysis. *Medicine* 2016; 95: e4598. doi: 10.1097/MD.0000000000004598.
22. Gutt CN, Oniu T, Mehrabi A, et al. Circulatory and respiratory complications of carbon dioxide insufflation. *Dig Surg* 2004; 21: 95-105. doi: 10.1159/000077038.
23. Kanchi M, Nair HC, Banakal S, Murthy K, Murugesan C. Haemodynamic response to endotracheal intubation in coronary artery disease: direct versus video laryngoscopy. *Indian J Anaesth* 2011; 55: 260-265. doi: 10.4103/0019-5049.82673.
24. Alkaya MA, Saraçoğlu KT, Pehlivan G, Eti Z, Göğüş FY. Effects of esmolol on the prevention of haemodynamic responses to tracheal extubation after craniotomy operations. *Turk J Anaesthesiol Reanim* 2014; 42: 86-90. doi: 10.5152/TJAR.2013.57.
25. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. *Gut Liver* 2012; 6: 172-187. doi: 10.5009/gnl.2012.6.2.172.